<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670032</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06. SPR. 18216</org_study_id>
    <nct_id>NCT01670032</nct_id>
  </id_info>
  <brief_title>Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo</brief_title>
  <official_title>A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaBay Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaBay Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a multicenter, randomized, vehicle controlled, parallel, group, double
      blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to
      one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel
      applied TID; Vehicle Topical Gel applied BID;Vehicle Topical Gel applied TID. All treatments
      will be administered for 7 days. Disease activity for the Target Lesion will be evaluated
      using the Skin Infection Rating Scale (SIRS) Score.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success at Follow up (Day 15) in the intent-to-treat (ITTC) population</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical Success is defined by the SIRS score of the Target Lesion</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>CD07223 1.5 % Topical Gel BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 1.5% CD07223 Topical Gel applied BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07223 1.5% Topical Gel TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 1.5% CD07223 Topical Gel applied TID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07223 vehicle gel BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: CD07223 Vehicle Topical Gel applied BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07223 vehicle gel TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: CD07223 Vehicle Topical Gel applied TID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: CD07223 1.5 % Topical Gel BID</intervention_name>
    <description>Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15</description>
    <arm_group_label>CD07223 1.5 % Topical Gel BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: CD07223 1.5% Topical Gel TID</intervention_name>
    <description>Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15</description>
    <arm_group_label>CD07223 1.5% Topical Gel TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: CD07223 vehicle gel BID</intervention_name>
    <description>Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15</description>
    <arm_group_label>CD07223 vehicle gel BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: CD07223 vehicle gel TID</intervention_name>
    <description>Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15</description>
    <arm_group_label>CD07223 vehicle gel TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 2 years of age or older

          -  Clinical diagnosis of primary impetigo (bullous or non bullous)

          -  Minimum diameter of Target Lesion to be one centimeter measured either as length or
             width.

          -  Presence of at least one and no more than ten lesions per subject at the time of
             screening

          -  The infected lesions' total area (as determined by the Investigator) must be less than
             100 cm2 in total area for subjects 18 years of age or older, or up to a maximum of 2%
             total body surface area for subjects younger than 18 years of age.

          -  Skin Infection Rating Scale (SIRS) total score of the Target Lesion of at least 4

        Exclusion Criteria:

          -  Presence of other active skin diseases at or near the Target Lesion area to be treated

          -  A subject whose disease is so widespread or severe that, in the opinion of the
             investigator, oral antibiotic treatment is needed

          -  Signs and symptoms of another current infection requiring antibiotic treatment

          -  Tympanic temperature at Screening/Baseline exceeding 38 degrees Celsius (100.4 degrees
             Fahrenheit) in a pediatric subject or 37.8 degrees Celsius (100 degrees Fahrenheit) in
             an adult subject

          -  History of Hepatitis B or C, HIV/ AIDS, or other immunodeficiency disease

          -  Concurrent or recent scabies infection or lice infestation (pediculosis) of the scalp

          -  Use of systemic antibiotics or systemic steroids within 14 days prior to study entry.
             A history of three or more courses of systemic antibiotics within the 3 month period
             immediately prior to screening will also be considered exclusionary

          -  Use of topical antibiotics, topical antibacterials, topical antifungals or topical
             steroids within 14 days prior to study entry on any skin lesion (as deemed significant
             by the Investigator by virtue of the lesion's nature and/or position to impact on the
             effectiveness of the study drug)

          -  Participation in any other clinical study or use of any investigational drugs or
             investigational device within 30 days prior to enrollment

          -  Presence of secondarily infected traumatic lesions (e.g. surgical wounds,
             animal/insect bites, burns, lacerations and abrasions).

          -  Another family member in same household currently enrolled in this study or another
             family member in the same household with active impetigo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SRCR, Inc</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care research Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Research, Inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cyn3rgy Research</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheraw Pediatrics, P.A.</name>
      <address>
        <city>Cheraw</city>
        <state>South Carolina</state>
        <zip>29520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research, Inc</name>
      <address>
        <city>Milan</city>
        <state>Tennessee</state>
        <zip>38358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sealy Urgent Care Center</name>
      <address>
        <city>Sealy</city>
        <state>Texas</state>
        <zip>77474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Langeberg Clinical Trials</name>
      <address>
        <city>Kraaifontein</city>
        <state>Cape Town</state>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newtown Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phelang Research Center</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0122</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Center</name>
      <address>
        <city>Soshanguve</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welkom Clinical Trial Center</name>
      <address>
        <city>Welkom</city>
        <state>Gauteng</state>
        <zip>9460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synopsis Research</name>
      <address>
        <city>Rondebosch</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <disposition_first_submitted>August 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 8, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 12, 2014</disposition_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

